Immunoassay for Neurological Biomarkers - Global Strategic Business Report 2026

The global market for Immunoassay for Neurological Biomarkers was valued at US$809.9 Million in 2025 and is projected to reach US$2.6 Billion by 2032, growing at a CAGR of 18.3% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Immunoassay for Neurological Biomarkers Market - Advancing Neurodiagnostics

Why Are Immunoassays Becoming Crucial in Neurology?

Immunoassays for neurological biomarkers are gaining significant traction due to their ability to detect and quantify proteins associated with neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The rising prevalence of these conditions, coupled with an aging population, has driven demand for early and accurate diagnostic tools. Immunoassays provide a non-invasive method for detecting neurological biomarkers in blood and cerebrospinal fluid, enabling timely intervention and disease management.

How Are Innovations in Immunoassay Technology Impacting the Market?

Technological advancements, including highly sensitive multiplex immunoassays and digital immunoassays, have improved the precision and scalability of neurological diagnostics. AI-driven data analysis is further refining biomarker detection, allowing for early-stage identification of neurological disorders. Moreover, the development of point-of-care immunoassay platforms is making neurodiagnostics more accessible, reducing dependency on specialized laboratory infrastructure. Portable and home-based diagnostic kits are also emerging, catering to patients who require regular monitoring.

What Are the Market Growth Factors?

The growing focus on early diagnosis of neurodegenerative diseases, increasing investment in biomarker research, and rising collaborations between pharmaceutical and diagnostic companies are major growth drivers in this market. Government initiatives promoting neurological research and advancements in personalized medicine are also contributing to the rapid expansion of immunoassay applications for neurological biomarker detection. Additionally, the pharmaceutical industry is leveraging immunoassays for drug development and clinical trials, further expanding their application.

What Lies Ahead for the Market?

Despite the promising growth, challenges such as regulatory hurdles, cost barriers, and standardization of biomarker panels need to be addressed. However, the increasing integration of AI, automation, and next-generation sequencing is expected to bridge these gaps. As demand for precision medicine grows, immunoassays for neurological biomarkers will play a pivotal role in transforming neurodiagnostics and patient care.

Report Scope

The report analyzes the Immunoassay for Neurological Biomarkers market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Product (Instruments Immunoassay for Neurological Biomarkers, Reagents Immunoassay for Neurological Biomarkers, Services Immunoassay for Neurological Biomarkers); Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis Disease, Other Diseases); Application (In Vitro Diagnostics Application, Research Application).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Instruments Immunoassay for Neurological Biomarkers segment, which is expected to reach US$1.6 Billion by 2032 with a CAGR of a 20.3%. The Reagents Immunoassay for Neurological Biomarkers segment is also set to grow at 15.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $220.6 Million in 2025, and China, forecasted to grow at an impressive 23.9% CAGR to reach $608.2 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Immunoassay for Neurological Biomarkers Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Immunoassay for Neurological Biomarkers Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Immunoassay for Neurological Biomarkers Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, ADx NeuroSciences NV, Banyan Biomarkers, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Immunoassay for Neurological Biomarkers market report include:

• Abbott Laboratories
• ADx NeuroSciences NV
• Banyan Biomarkers, Inc.
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• C2N Diagnostics
• EnCor Biotechnology Inc.
• F. Hoffmann-La Roche Ltd
• Fujirebio
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Nimble Therapeutics
• PerkinElmer, Inc.
• QIAGEN N.V.
• Quanterix Corporation
• Quibim
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.